NOCIL Limited

9%

Revenues has seen substantial growth Fixed cost absorption improved Revenue growth in FY21 is 9% compared to FY20 EBITDA margins will improve gradually ¢ Volume growth in FY21 is 14% compared

14%

in FY21 is 9% compared to FY20 EBITDA margins will improve gradually ¢ Volume growth in FY21 is 14% compared to FY20 Ke Responsible Care’ 3 Quarterly Performance: Stron

3%

ave crossed pre-COVID levels on monthly run rate basis * Sequential volume growth in Q4FY21 is 3% ¢ ¢ ¢ ¢ ¢ Achieved Highest ever quarterly revenues with substantial growth in in Q4 S

17%

t ever quarterly revenues with substantial growth in in Q4 Sequential revenue growth in Q4FY21 is 17% Fixed cost absorption improved Highest EBITDA in last 7 quarters EBITDA margins improved sequ

44.2%

erations Raw Material Value Addition * 322 180 142 213 106 106 Value Addition % 44.2% 50.0% Employee Expenses Other Operating Expenses Operating EBITDA 17 75 50 17 53

50.0%

Raw Material Value Addition * 322 180 142 213 106 106 Value Addition % 44.2% 50.0% Employee Expenses Other Operating Expenses Operating EBITDA 17 75 50 17 53 37 5

51%

% Employee Expenses Other Operating Expenses Operating EBITDA 17 75 50 17 53 37 51% 34% 37% 275 155 119 43.4% 18 64 37 17% 19% 35% 925 505 420 846 38

34%

ployee Expenses Other Operating Expenses Operating EBITDA 17 75 50 17 53 37 51% 34% 37% 275 155 119 43.4% 18 64 37 17% 19% 35% 925 505 420 846 388 45

37%

Expenses Other Operating Expenses Operating EBITDA 17 75 50 17 53 37 51% 34% 37% 275 155 119 43.4% 18 64 37 17% 19% 35% 925 505 420 846 388 458 45

43.4%

ing Expenses Operating EBITDA 17 75 50 17 53 37 51% 34% 37% 275 155 119 43.4% 18 64 37 17% 19% 35% 925 505 420 846 388 458 45.4% 54.2% 67 226 1

19%

DA 17 75 50 17 53 37 51% 34% 37% 275 155 119 43.4% 18 64 37 17% 19% 35% 925 505 420 846 388 458 45.4% 54.2% 67 226 127 74 208 176 Opera

35%

7 75 50 17 53 37 51% 34% 37% 275 155 119 43.4% 18 64 37 17% 19% 35% 925 505 420 846 388 458 45.4% 54.2% 67 226 127 74 208 176 Operating E

Liquidity position

1

Investor Relations Advisors

1

Liquidity position

* Company has comfortable liquidity position Mask & Sanitization distribution & compulsion * Compulsion for the use of mask and hand sanitization every 2 hours and following all the protocols and guidelines * Company is debt free and are taking care of its working capital requirements through internal accruals (ES) e Vv, Responsible Care’ Standalone Profit & Loss Statement NOcIL LIMITED ARVIND MAFATLAL GROUP The ethics of excellence Rs. In Crores ot Oa Q4FY20 Q3FY21 Rte Net Revenue from Operations Raw Material Value Addition * 322 180 142 213 106 106 Value Addition % 44.2% 50.0% Employee Expenses Other Operating Expenses Operating EBITDA 17 75 50 17 53 37 51% 34% 37% 275 155 119 43.4% 18 64 37 17% 19% 35% 925 505 420 846 388 458 45.4% 54.2% 67 226 127 74 208 176 Operating EBITDA Margin 15.6% 17.3% 13.6% 13.7% 20.8% _ Depreciation Interest Other Income Profit Before Tax Tax Net Profit 10 0* 2 43 7 36 9 0* 3 31 8 22 9 0* 1 29 7 22 36 1 14 104 18 86 32 1 10 152 21 131 45% 63% 39% 61% Net

Investor Relations Advisors

NOCIL Ltd. CIN: L99999MH1961PLCO012003 Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285 Mr. P. Srinivasan - CFO finance@nocil.com Ms. Mugdha Khare mugdha.khare@nocil.com Mr. Jigar Kavaiya Jigar. kavaiya@sgapl.net +91 9920602034 www.nocil.com www.sgapl.net 2 Responsible Care® 27